We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.
With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.
Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.
We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releaseA US based company, involved in the development of new therapies for patients with severe neurological diseases affecting movement, in a clinical study involving sensitive genetic data.
Actualités et publications récentes
Word on the street at the J.P. Morgan Healthcare Conference 2025
par plusieurs auteurs
What will 2025 bring for pharma & biotech patents?
5 Things to watch out for life sciences practitioners.
Life sciences M&A roundup: October 2024
par Ross McNaughton et Sarah Cole
Reporting clinical trial results to the market
par plusieurs auteurs
Life sciences M&A roundup: September 2024
par Ross McNaughton et Sarah Cole
Événements connexes